Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 2

1(20.0%)

5Total

N/A(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07424950Phase 2Not Yet Recruiting

Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis

Role: lead

NCT03191370Not ApplicableCompleted

Distraction Technique to Reduce Discomfort of Transnasal Fiberoptic Laryngoscopy

Role: lead

NCT02300012Not ApplicableCompleted

A Pilot Study to Investigate Biomarkers in Anterior Cruciate Ligament (ACL) Patients and Healthy Controls

Role: lead

NCT04057560Unknown

Metabolomics in Small Intestinal Bacterial Overgrowth

Role: lead

NCT03920124Not ApplicableCompleted

Feasibility of Interval Exercise in Bronchiectasis

Role: collaborator

NCT02342522Not ApplicableCompleted

Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PPCI (CONDI2/ERIC-PPCI)

Role: collaborator

All 6 trials loaded